{
    "relation": [
        [
            "",
            "SOF+PEG+RBV 12 Weeks",
            "SOF+PEG+RBV 24 Weeks",
            "SOF+PEG+RBV 12 Week/Rerandomization Group"
        ],
        [
            "Description",
            "Participants were randomized to receive SOF 400 mg+PEG 180 \u00b5g+RBV 1000-1200 mg for 12 weeks.",
            "Participants were randomized to receive SOF 400 mg+PEG 180 \u00b5g+RBV 1000-1200 mg for 24 weeks.",
            "Participants were randomized to receive SOF 400 mg+PEG 180 \u00b5g+RBV 1000-1200 mg for 12 weeks, then were rerandomized to receive SOF monotherapy or SOF+RBV for 12 additional weeks."
        ]
    ],
    "pageTitle": "Sofosbuvir With Pegylated Interferon and Ribavirin Hepatitis C Virus (HCV) Genotypes 1,4,5,6 - Study Results - ClinicalTrials.gov",
    "title": "",
    "url": "https://clinicaltrials.gov/ct2/show/results/NCT01329978?sect=Xh0156&view=results",
    "hasHeader": true,
    "headerPosition": "MIXED",
    "tableType": "RELATION",
    "tableNum": 25,
    "s3Link": "common-crawl/crawl-data/CC-MAIN-2015-32/segments/1438042988930.94/warc/CC-MAIN-20150728002308-00274-ip-10-236-191-2.ec2.internal.warc.gz",
    "recordEndOffset": 869994627,
    "recordOffset": 869973761,
    "tableOrientation": "HORIZONTAL",
    "textBeforeTable": "Reporting Groups 589 participants were screened and 332 were randomized and treated, and comprise the Safety Analysis Set. Significant events and approaches for the overall study following participant enrollment, but prior to group assignment Pre-Assignment Details Participants were enrolled in a total of 42 study sites in the United States. The first participant was screened on 23 March 2011. The last participant observation was on 27 August 2012. Key information relevant to the recruitment process for the overall study, such as dates of the recruitment period and locations Recruitment Details \u00a0 Hide Participant Flow \u00a0 Participant Flow Drug: Sofosbuvir Drug: RBV Drug: PEG Interventions: Hepatitis C, Chronic Condition: Allocation:\u00a0Randomized; \u00a0 Endpoint\u00a0Classification:\u00a0Safety/Efficacy\u00a0Study; \u00a0 Intervention\u00a0Model:\u00a0Parallel\u00a0Assignment; \u00a0 Masking:\u00a0Open\u00a0Label; \u00a0 Primary\u00a0Purpose:\u00a0Treatment Study",
    "textAfterTable": "SOF Rerandomization Group This group includes participants in the SOF+PEG+RBV 12 week/Rerandomization Group who were rerandomized to receive SOF 400 mg monotherapy for 12 additional weeks. SOF+RBV Rerandomization Group This group includes participants in the SOF+PEG+RBV 12 week/Rerandomization Group who were rerandomized to receive SOF 400 mg+RBV 1000-1200 for 12 additional weeks. Participant Flow for 2 periods Period 1: \u00a0 Sofosbuvir+PEG+RBV Treatment Period \u00a0 \u00a0 SOF+PEG+RBV 12 Weeks \u00a0 \u00a0 SOF+PEG+RBV 24 Weeks \u00a0 \u00a0 SOF+PEG+RBV 12 Week/Rerandomization Group \u00a0 \u00a0 SOF Rerandomization Group \u00a0 \u00a0 SOF+RBV Rerandomization Group \u00a0 STARTED \u00a0 \u00a0 52 \u00a0 \u00a0 125 \u00a0 \u00a0 155 \u00a0 \u00a0 0 \u00a0 \u00a0 0 \u00a0 COMPLETED \u00a0 \u00a0 48 [1] \u00a0 112",
    "hasKeyColumn": false,
    "keyColumnIndex": -1,
    "headerRowIndex": 0
}